Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Goodwill (2023 - 2026)

Cartesian Therapeutics (RNAC) has disclosed Goodwill for 4 consecutive years, with $48.2 million as the latest value for Q1 2026.

  • For Q1 2026, Goodwill changed 0.0% year-over-year to $48.2 million; the TTM value through Mar 2026 reached $48.2 million, changed 0.0%, while the annual FY2025 figure was $48.2 million, 0.0% changed from the prior year.
  • Goodwill hit $48.2 million in Q1 2026 for Cartesian Therapeutics, roughly flat from $48.2 million in the prior quarter.
  • Across five years, Goodwill topped out at $48.2 million in Q4 2023 and bottomed at $48.2 million in Q4 2023.
  • Average Goodwill over 4 years is $48.2 million, with a median of $48.2 million recorded in 2023.
  • On a YoY basis, Goodwill climbed as much as 0.0% in 2024 and fell as far as 0.0% in 2024.
  • Cartesian Therapeutics' Goodwill stood at $48.2 million in 2023, then changed by 0.0% to $48.2 million in 2024, then changed by 0.0% to $48.2 million in 2025, then changed by 0.0% to $48.2 million in 2026.
  • According to Business Quant data, Goodwill over the past three periods came in at $48.2 million, $48.2 million, and $48.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.